Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness

View ORCID ProfileFritz Obermeyer, View ORCID ProfileMartin Jankowiak, Nikolaos Barkas, View ORCID ProfileStephen F. Schaffner, View ORCID ProfileJesse D. Pyle, View ORCID ProfileLonya Yurkovetskiy, View ORCID ProfileMatteo Bosso, View ORCID ProfileDaniel J. Park, View ORCID ProfileMehrtash Babadi, Bronwyn L. MacInnis, View ORCID ProfileJeremy Luban, Pardis C. Sabeti, Jacob E. Lemieux
doi: https://doi.org/10.1101/2021.09.07.21263228
Fritz Obermeyer
1Broad Institute of MIT and Harvard; 415 Main Street, Cambridge, MA 02142, USA
2Pyro Committee, Linux AI & Data Foundation; 548 Market St San Francisco, California 94104
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fritz Obermeyer
  • For correspondence: lemieux@broadinstitute.org fobermey@broadinstitute.org
Martin Jankowiak
1Broad Institute of MIT and Harvard; 415 Main Street, Cambridge, MA 02142, USA
2Pyro Committee, Linux AI & Data Foundation; 548 Market St San Francisco, California 94104
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martin Jankowiak
Nikolaos Barkas
1Broad Institute of MIT and Harvard; 415 Main Street, Cambridge, MA 02142, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen F. Schaffner
1Broad Institute of MIT and Harvard; 415 Main Street, Cambridge, MA 02142, USA
3Department of Organismic and Evolutionary Biology, Harvard University; Cambridge, MA 02138, USA
4Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Harvard University; Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stephen F. Schaffner
Jesse D. Pyle
1Broad Institute of MIT and Harvard; 415 Main Street, Cambridge, MA 02142, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jesse D. Pyle
Lonya Yurkovetskiy
5Program in Molecular Medicine, University of Massachusetts Medical School; Worcester, MA 01605, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lonya Yurkovetskiy
Matteo Bosso
5Program in Molecular Medicine, University of Massachusetts Medical School; Worcester, MA 01605, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matteo Bosso
Daniel J. Park
1Broad Institute of MIT and Harvard; 415 Main Street, Cambridge, MA 02142, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel J. Park
Mehrtash Babadi
1Broad Institute of MIT and Harvard; 415 Main Street, Cambridge, MA 02142, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mehrtash Babadi
Bronwyn L. MacInnis
1Broad Institute of MIT and Harvard; 415 Main Street, Cambridge, MA 02142, USA
4Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Harvard University; Boston, MA, USA
6Massachusetts Consortium on Pathogen Readiness; Boston, MA 02115, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy Luban
1Broad Institute of MIT and Harvard; 415 Main Street, Cambridge, MA 02142, USA
5Program in Molecular Medicine, University of Massachusetts Medical School; Worcester, MA 01605, USA
6Massachusetts Consortium on Pathogen Readiness; Boston, MA 02115, USA
7Ragon Institute of MGH, MIT, and Harvard; 400 Technology Square, Cambridge, MA 02139, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jeremy Luban
Pardis C. Sabeti
1Broad Institute of MIT and Harvard; 415 Main Street, Cambridge, MA 02142, USA
3Department of Organismic and Evolutionary Biology, Harvard University; Cambridge, MA 02138, USA
4Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Harvard University; Boston, MA, USA
6Massachusetts Consortium on Pathogen Readiness; Boston, MA 02115, USA
8Howard Hughes Medical Institute; 4000 Jones Bridge Rd, Chevy Chase, MD 20815, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacob E. Lemieux
1Broad Institute of MIT and Harvard; 415 Main Street, Cambridge, MA 02142, USA
9Division of Infectious Diseases, Massachusetts General Hospital; Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lemieux@broadinstitute.org fobermey@broadinstitute.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Repeated emergence of SARS-CoV-2 variants with increased fitness necessitates rapid detection and characterization of new lineages. To address this need, we developed PyR0, a hierarchical Bayesian multinomial logistic regression model that infers relative prevalence of all viral lineages across geographic regions, detects lineages increasing in prevalence, and identifies mutations relevant to fitness. Applying PyR0 to all publicly available SARS-CoV-2 genomes, we identify numerous substitutions that increase fitness, including previously identified spike mutations and many non-spike mutations within the nucleocapsid and nonstructural proteins. PyR0 forecasts growth of new lineages from their mutational profile, identifies viral lineages of concern as they emerge, and prioritizes mutations of biological and public health concern for functional characterization.

One Sentence summary A Bayesian hierarchical model of all SARS-CoV-2 viral genomes predicts lineage fitness and identifies associated mutations.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Study is based on SARS-CoV-2 genetic sequences publicly available at GISAID.org.

Clinical Protocols

https://github.com/broadinstitute/pyro-cov

Funding Statement

This work was sponsored by the U.S. Centers for Disease Control and Prevention (BAA), as well as support from the Doris Duke Charitable Foundation (J.E.L.), the Howard Hughes Medical Institute (P.C.S.), and the Evergrande COVID-19 Response Fund Award from the Massachusetts Consortium on Pathogen Readiness (J.L.).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was conducted using data from a public database (GISAID). No IRB approval is necessary.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • 1. We used our model to conduct a global analysis of variants and case counts during the entire first two years of the SARS-CoV-2 pandemic, extending the analysis to include data from the beginning of the outbreak through to January 2022 (rather than through July 2021). 2. Our data now includes 6.4 million genomes, over 3x times the size of our original study, and by far the largest genomic analysis for SARS-CoV-2 or any virus to date. 3. The updated model closely covers the emergence of Omicron and includes a detailed analysis of relative fitness of the Omicron sublineages, BA.1, BA.2, and BA.3, predicting BA.2 as the fittest lineage, a prediction that seems in line with current events. 3. We have completely rewritten the initial clustering method for the model to use a fine-grained, phylogenetic approach, improving on the previous approach that was based on PANGO lineages. The new clustering method recapitulates our earlier, PANGO-based findings, reveals heterogeneity within lineages, and captures these effects in the model to improve the inference. 4. We have added experimental data to probe and validate our findings, including assessment of several high-scoring mutations in cellular infectivity assays. We found that high-scoring spike RBD mutations do not consistently enhance infectivity; rather, they appear to confer immune escape. 5. We have further expanded our analysis of potential mechanisms driving fitness, by correlating immune escape predictions with our mutational fitness predictions. 6. On the basis of these new data and analyses, we have broadened the scope of our discussion to highlight the major forces dominating the pandemic during its first two years, and in particular the recent transition to an immune escape phase. 7. We have added new structural analyses and figures, showing that mutational fitness changes are highly concentrated in specific structural regions of proteins, especially spike, nucleocapsid, and ORF1a. 8. We have rewritten key parts of the manuscript to speak to the broader implications of our work for basic science and public health.

Data Availability

All data was gathered from other public resources. Data preprocessing scripts are open source.

https://gisaid.org

https://github.com/CSSEGISandData/COVID-19

https://cov-lineages.org/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted February 16, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness
Fritz Obermeyer, Martin Jankowiak, Nikolaos Barkas, Stephen F. Schaffner, Jesse D. Pyle, Lonya Yurkovetskiy, Matteo Bosso, Daniel J. Park, Mehrtash Babadi, Bronwyn L. MacInnis, Jeremy Luban, Pardis C. Sabeti, Jacob E. Lemieux
medRxiv 2021.09.07.21263228; doi: https://doi.org/10.1101/2021.09.07.21263228
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness
Fritz Obermeyer, Martin Jankowiak, Nikolaos Barkas, Stephen F. Schaffner, Jesse D. Pyle, Lonya Yurkovetskiy, Matteo Bosso, Daniel J. Park, Mehrtash Babadi, Bronwyn L. MacInnis, Jeremy Luban, Pardis C. Sabeti, Jacob E. Lemieux
medRxiv 2021.09.07.21263228; doi: https://doi.org/10.1101/2021.09.07.21263228

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1094)
  • Dentistry and Oral Medicine (195)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9760)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2304)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1554)
  • Health Policy (734)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (502)
  • Infectious Diseases (except HIV/AIDS) (11637)
  • Intensive Care and Critical Care Medicine (616)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2140)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1173)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (309)
  • Pediatrics (694)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (266)
  • Psychiatry and Clinical Psychology (2176)
  • Public and Global Health (4649)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (456)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (250)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)